Biopolym. Cell. 2019; 35(5):333-339.
http://dx.doi.org/10.7124/bc.000A10
Molecular Biomedicine
Set of STR-markers for 6p21.31 chromosomal region linkage analysis and CNV study
1Hryshchenko N. V., 2Kirichenkova O. P., 1Gordiyk V. V., 1Kravchenko S. A., 1, 3Kashuba V. I.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03143
  2. Educational and Scientific Center "Institute of Biology and Medicine",
    Taras Shevchenko National University of Kyiv
    64/13, Volodymyrska Str., Kyiv, Ukraine, 01601
  3. Karolinska Institutet
    Stockholm SE-171 77, Sweden

Abstract

Aim. To create a panel of informative STR-markers in HLA locus for the analysis of genomic rearrangements in different types of malignant tumors as well as for the selection of the HLA matched sibling for allogeneic transplantation. Methods. The preliminary screening of six presumed STR-markers located in the proximal, central and distal parts of the HLA chromosome region (6p21.31) was performed by agarose gel electrophoresis of the PCR-fragments. The accurate genotyping of the most promising STR-markers was carried out by electrophoretic separation of the PCR-fragments in a polyacrylamide gel on an automatic laser analyzer. Results. Based on the obtained results we have selected three STRs with the highest heterozygosity indexes (HI): D6S2678 – HLA class I (HI=91.4 %), DQIV – class II (HI=62.8 %) and D6S2925 – class III (HI=74.3 %) as potential markers for linkage and CNV study. Conclusion. We have demonstrated that the selected panel of markers allows us to effectively solve both tasks: detection of somatic rearrangements in different parts of HLA locus in tumor samples and HLA-haplotype determination to select a suitable related donor for transplantation.
Full text: (PDF, in English)

References

[1] Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, Solit D, Berger M, Zhou R, Rizvi NA, Chan TA. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359(6375):582-587.
[2] Doonan BP, Haque A. Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design. J Clin Cell Immunol. 2015;6(4). pii: 351.
[3] Scepanovic P, Alanio C, Hammer C, Hodel F, Bergstedt J, Patin E, Thorball CW, Chaturvedi N, Charbit B, Abel L, Quintana-Murci L, Duffy D, Albert ML, Fellay J; Milieu Intérieur Consortium. Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Med. 2018;10(1):59.
[4] Howard CA, Fernandez-Vina MA, Appelbaum FR, Confer DL, Devine SM, Horowitz MM, Mendizabal A, Laport GG, Pasquini MC, Spellman SR. Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2015;21(1):4-7.
[5] Willems T, Gymrek M, Highnam G; 1000 Genomes Project Consortium, Mittelman D, Erlich Y. The landscape of human STR variation. Genome Res. 2014;24(11):1894-904.
[6] Kashuba V, Dmitriev AA, Krasnov GS, Pavlova T, Ignatjev I, Gordiyuk VV, Gerashchenko AV, Braga EA, Yenamandra SP, Lerman M, Senchenko VN, Zabarovsky E. NotI microarrays: novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer. Int J Mol Sci. 2012;13(10):13352-77.
[7] Fesai OA, Kravchenko SA, Tyrkus MY, Makukh GV, Zinchenko VM, Strelko GV, Livshits LA. CAG polymorphism of the androgen receptor gene in azoospermic and oligozoospermic men from Ukraine. Cytol Genet. 2009; 43:401–5.
[8] Bick SL, Bick DP, Wells BE, Roesler MR, Strawn EY, Lau EC. Preimplantation HLA haplotyping using tri-, tetra-, and pentanucleotide short tandem repeats for HLA matching. J Assist Reprod Genet. 2008;25(7):323-31.
[9] Cullen M, Malasky M, Harding A, Carrington M. High-density map of short tandem repeats across the human major histocompatibility complex. Immunogenetics. 2003;54(12):900-10.
[10] Deakin JE, Papenfuss AT, Belov K, Cross JG, Coggill P, Palmer S, Sims S, Speed TP, Beck S, Graves JA. Evolution and comparative analysis of the MHC Class III inflammatory region. BMC Genomics. 2006;7:281.